Thomas Haberl

Thomas Haberl

Auto-generated profile, based on publicly available information

Thomas Haberl

Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
ICIuliana Coti
Iuliana Coti
CSChristoph Schukro
Christoph Schukro
FDFitim Drevinja
Fitim Drevinja
THThomas Haberl
Thomas Haberl
AKAlexandra Kaider
Alexandra Kaider
MAMartin Andreas
Martin Andreas
The implantation of rapid-deployment aortic valves may interfere with the conduction system of the heart. This study evaluates the occurrence and predictive factors of conduction anomalies in patients undergoing surgical aortic valve replacement (SAVR) with a rapid-deployment balloon-expandable bioprosthesis in a single-center, real-world experience. Between May 2010 and April 2019, 700 consecutive patients were included in a prospective, ongoing database with a longitudinal follow-up preoperatively, at discharge, and at 3 months, 1 year, 3 years, and 5 years postoperatively. Thirty-seven patients (5.3%) had a permanent pacemaker at baseline and were excluded from further analysis, leaving 663 patients for analysis. Assessment of conduction anomalies was performed by electrocardiography (ECG) monitoring and repeated 12-lead ECG during the hospital stay and at postoperative follow-ups. Preoperatively, 126 patients (19.0%) presented with different conduction disturbances. New permanent pacemaker implantation (PPI) occurred in 61 patients during the first 14 days (cumulative incidence, 9.4%). The indication for PPI was complete atrioventricular block in 47 cases (77%). Preoperative conduction anomalies, such as right bundle branch block, as well as operative characteristics (concomitant procedures) were found to be independent predictors for new PPI. One-year survival was 98% in patients with new early PPI and 96% in those without new early PPI (P = .60). The PPI rate was in the range of previous reports for rapid-deployment prostheses. PPI did not have a significant influence on short- to intermediate-term survival. Case selection with exclusion of patients presenting with baseline conduction disturbances may decrease the rate of new PPIs after SAVR with rapid-deployment balloon-expandable bioprostheses.

22 May 2020 in Transplant International
Verified
Journal Article
Open access
PDF file
EOEmilio Osorio-Jaramillo
Emilio Osorio-Jaramillo
GHGeert W. Haasnoot
Geert W. Haasnoot
AKAlexandra Kaider
Alexandra Kaider
ASAnne‐Kristin Schaefer
Anne‐Kristin Schaefer
THThomas Haberl
Thomas Haberl
AAArezu Z. Aliabadi‐Zuckermann
Arezu Z. Aliabadi‐Zuckermann
Background The aim was to evaluate the association of molecular‐level human leukocyte antigen (HLA) mismatching with post‐transplant graft survival, rejection and cardiac allograft vasculopathy (CAV). Methods We retrospectively analysed all primary cardiac transplant recipients between 01/1984‐06/2016. 1,167 patients fulfilled inclusion criteria and had HLA typing information available. In 312 donor‐recipient pairs, typing at serological split antigen level was available. We used the Epitope MisMatch Algorithm to calculate the number of amino acid differences in antibody‐verified HLA eplets (amino acid mismatch‐load (AAMM)) between donor and recipient. Results Patients with a higher HLA‐DR AAMM load had inferior 1‐year graft survival (hazard ratio [HR], 1.14; 95% confidence interval [CI], 1.01‐1.28). The HLA‐AB AAMM load showed no impact on graft survival. In the subgroup with available split‐level information, we observed an inferior graft survival for a higher HLA‐DR AAMM load 3 months after transplantation (HR, 1.22; 95% CI, 1.04‐1.44) and a higher risk for rejection for an increasing HLA‐AB (HR, 1.70; 95% CI, 1.29‐2.24) and HLA‐DR (HR, 1.32; 95% CI, 1.09‐1.61) AAMM load. No impact on the development of CAV was found. Conclusions Molecular‐level HLA mismatch analysis could serve as a tool for risk stratification after heart transplantation and might take us one step further into precision medicine.

28 December 2021 in Medicina
Verified
Journal Article
Open access
PDF file
JRJulia Riebandt
Julia Riebandt
THThomas Haberl
Thomas Haberl
KDKlaus Distelmaier
Klaus Distelmaier
Martin Hermann BernardiMartin Hermann Bernardi
Martin Hermann Bernardi
ASAnne-Kristin Schaefer
Anne-Kristin Schaefer
Dominik WiedemannDominik Wiedemann
Dominik Wiedemann
Background and objectives: Extracorporeal life support (ECLS) is a widely accepted and effective strategy for use in patients presenting with refractory cardiogenic shock. Implantation in awake and non-intubated patients allows for optimized evaluation of further therapy options while avoiding potential side effects associated with the need for sedation and intubation. The aim of the study was the assessment of safety and feasibility of awake ECLS implementation and of outcomes in patients treated with this concept. Materials and Methods: We retrospectively reviewed the concept of awake ECLS implantation in 16 consecutive patients (mean age 58 ± 8 years; male: 88%; ischemic cardiomyopathy: 50%) from 02/2017 to 01/2021. Study endpoints were survival to weaning or bridging to durable support or organ replacement and development of end-organ function and hemodynamic parameters on ECLS. Results: Fourteen patients (88%) were able to be successfully transitioned to definite therapy options. ECLS support stabilized end-organ function, led to a decrease in mean lactate levels (5.3 ± 3.7 mmol/L at baseline to 1.9 ± 1.3 mmol/L 12 h after ECLS start; p = 0.01) and improved hemodynamics (median central venous pressure 20 ± 5 mmHg vs. 10 ± 2 mmHg, p = 0.001) over a median duration of two days (1–8 days IQR). Two patients (13%) died on ECLS support due to multi-organ dysfunction syndrome. Survival to discharge of initially successfully bridged or weaned patients was 64%. Conclusions: Awake ECLS implantation is feasible and safe with the key advantage of omitting or delaying general anesthesia and intubation, with their associated risks in cardiogenic-shock patients, facilitating further decision making.

24 February 2018 in Indian Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
PDF file
Dominik WiedemannDominik Wiedemann
Dominik Wiedemann
THThomas Haberl
Thomas Haberl
PAPhilipp Angleitner
Philipp Angleitner
KDKamen Dimitrov
Kamen Dimitrov
GLGünther Laufer
Günther Laufer
DZDaniel Zimpfer
Daniel Zimpfer
The era of intracorporal continuous flow pumps has initiated significant success of left ventricular assist device (LVAD) surgery. However, median sternotomy has been the only surgical approach for implantation over many years. During the last decade, less-invasive access ways gained popularity. Within this review, we describe our own clinical experience in minimally invasive ventricular assist device (VAD) surgery and summarize the current scientific literature on this topic.

1 January 2017 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Open access
KDK. Dimitrov
K. Dimitrov
JRJulia Riebandt
Julia Riebandt
Dominik WiedemannDominik Wiedemann
Dominik Wiedemann
RMRoxana Moayedifar
Roxana Moayedifar
PSP. Simon
P. Simon
Daniel ZimpferDaniel Zimpfer
Daniel Zimpfer
Objectives: Micro-emboli are detectable as high intensity transient signals (HITS) with Doppler ultrasound in different clinical conditions including patients with left ventricular assist devices (LVAD). In LVAD patients HITS represent micro-emboli of mostly gaseous nature. The cause of their formation, however, has not been determined. Methods: From June 2014 to September 2016 LVAD patients were systematically screed for HITS in the LVAD outflow graft by transthoracic echocardiography. The occurrence of HITS was then correlated with pump thrombus formation (PT) and non-thrombotic outflow graft occlusion. Results: HITS were detected in the outflow graft of 20 LVAD patients (Thoratec Heartmate II n = 12, Heartware HVAD n = 8). HITS correlated with PT in 14 patients (Heartmate II n = 7, HVAD n = 7) and non-thrombotic outflow graft stenosis in 6 patients (Heartmate II n = 5, HVAD n = 1). Patients with PT either underwent thrombolysis (n = 7), pump exchange (n = 2), LVAD weaning (n = 1) or no treatment if no hard clinical treatment indication was present (n = 5). In PT patients HITS disappeared after successful thrombolysis or pump exchange. Of note, pump thrombus formation or non-thrombotic outflow graft stenosis could be macroscopically assured at the time of transplant in the remaining patients. Conclusion: HITS detection by transthoracic echocardiography identifies patients with pump thrombus formation and non-thrombotic outflow graft occlusion and might develop as a very sensitive screening tool for pump pathology and hypocoagulation monitoring.

23 January 2013 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
THT Haberl
T Haberl
SMS Mahr
S Mahr
JRJulia Riebandt
Julia Riebandt
GLG Laufer
G Laufer
ARA Rajek
A Rajek
Daniel ZimpferDaniel Zimpfer
Daniel Zimpfer
Objective: A median sternotomy is the standard incision for left ventricular assist device (LVAD) implantation. There are some theoretical advantages of avoiding a median sternotomy in LVAD patients including better right ventricular protection, improved pulmonary function and faster recovery. The present study was designed to evaluate a novel, minimally invasive sternotomy sparing technique for LVAD implantation. Methods: From February 2012 to September 2012 10 patients (mean age 55.5 ± 11.1yrs., 90% male, ischemic heart disease 70%, prior cardiac surgery 10%) with terminal heart failure (Intermacs level 1: 30%, level 2 10%, level 3 40%, level 4 – 7 20%) underwent minimally invasive isolated sternotomy sparing LVAD implantation (Heartware® HVAD n = 9, Thoratect® HMII n = 1). Surgical access was established by a left minithoracotomy directly over the apex, the outflow graft was tunneled to the aorta intrapericardially in all but redo cases. The aortic outflow anastomosis was performed via a right minithoracotomy in the 2nd intercostal space. Circulatory support for LVAD implantation was performed using CPB or ECMO. Results: Sternotomy sparing LVAD implantation was feasible in all patients with no need for conversions. Thirty-day and in-hospital mortality was 0%. Median time on respirator was 2.2 ± 3.4 days, overall in-hospital stay was 32.6 ± 8.5 days. One patient (10%) died during follow-up from pump thrombus formation. One patient underwent surgical revision for postoperative bleeding (retroperitoneal haematoma). We observed no permanent neurological deficits and relevant infections. Conclusion: Minimally invasive sternotomy sparing left ventricular assist device implantation is feasible and safe. The very encouraging results obtained in this initial series justify a broad application of this technique.